Loading…
Provides home- and community-based health services (home health, hospice, personal/behavioral care) and pharmacy services to complex, chronic-care patients.
Provides home- and community-based health services (home health, hospice, personal/behavioral care) and pharmacy services to complex, chronic-care patients.
Pharmacy Solutions carries most of the revenue by filling specialty and infusion drug orders for chronic-care patients, billed to insurers and government programs, while Provider Services is paid mostly by Medicaid and Medicare for care delivered at home or in community settings. KKR is the controlling shareholder.
Moat: narrow (scale, distribution, regulatory licence). Broad national footprint of licensed home/community-care sites and pharmacy operations serving complex patients.
Headquarters: Louisville, Kentucky, USA · Founded: 1974 · Employees: 23,500
Size BrightSpring Health Services (BTSG) is a United States Health Care company (Medical/Nursing Services) with a market value of $13.4B, the 653rd largest of 3,117 United States companies the cockpit tracks. Shares closed at $67.15 on 6 Nov 2026.
Performance Over six months the shares gained 22.5%, against +27.7% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 22.9% over the last twelve months (peer median +7.9%); the operating margin is 3.9% (peer median 9.8%).
Valuation It trades at 28.3× forward earnings against a peer median of 20.8× (8th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points below its cost of capital (12.5% WACC).
Short interest Short interest is 5.8% of the free float (15 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $15.3B | $12.9B | $10.1B | $8.83B | $7.72B |
| Revenue growth | — | +28% | +14% | +14% | — |
| Gross profit | $1.91B | $1.52B | $1.27B | $1.43B | $1.35B |
| EBITDA | $754M | $572M | $428M | $392M | $500M |
| Net income | $339M | $191M | -$18.1M | -$155M | -$53.9M |
| Free cash flow | $489M | $395M | -$57.1M | $137M | -$74.8M |
| Capital expenditure | $110M | $95.5M | $80.9M | $73.5M | $70.1M |
| Total debt | $2.38B | $2.71B | $2.79B | $3.67B | $3.68B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BrightSpring Health Services BTSG | $13.4B | +22% | +23% | 4% | 28.3× | 24.2% |
| Option Care Health OPCH | $4.74B | +54% | +4% | 6% | 15.6× | 1.5% |
| Addus HomeCare ADUS | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% |
| Aveanna Healthcare AVAH | $2.89B | +97% | +20% | 11% | 15.4× | 13.4% |
| Pennant PNTG | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% |
| Chemed CHE | $6.87B | +24% | +5% | 14% | 19.5× | 2.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BTSG | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.5% | +11.8% | 6th lowest of 19 |
| 6-month return | +22.5% | +27.7% | 7th lowest of 19 |
| Distance from 52-week high | -8.9% | -9.7% | 10th highest of 19 |
| Revenue growth (TTM) | +22.9% | +7.9% | 3rd highest of 19 |
| Operating margin | 3.9% | 9.8% | 2nd lowest of 19 |
| Forward P/E | 28.3× | 20.8× | 8th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 24.2% | 11.8% | 6th most demanding of 17 |
| Growth delivered (Del g) | +18.3% | +12.5% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | +6.0 pp | -0.6 pp | 5th most demanding of 17 |
| ROIC minus cost of capital | -0.3 pp | +0.6 pp | 8th lowest of 19 |
| Net debt / EBITDA | 2.2× | 2.8× | 6th least indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BrightSpring Health Services BTSG | United States | $13.4B | +22% | +23% | 4% | 28.3× | 24.2% | +18.3% |
| Encompass Health EHC | United States | $13.5B | +30% | +9% | 18% | 20.5× | 5.6% | +5.0% |
| Fresenius Medical Care FME.DE | Germany | $12.6B | +14% | 0% | 11% | 10.4× | -3.6% | +1.9% |
| Aier Eye Hospital 300015.SZ | China | $12.5B | -16% | +5% | 21% | 29.5× | 11.7% | +13.4% |
| DaVita DVA | United States | $12.0B | -4% | +6% | 15% | 11.9× | -1.1% | +3.4% |
| Solventum SOLV | United States | $15.4B | +23% | -1% | 8% | 12.2× | n/a | n/a |
| Ensign ENSG | United States | $10.6B | +6% | +17% | 9% | 21.1× | 12.0% | +16.5% |
| Sonic Healthcare SHL.AX | Australia | $6.87B | +6% | +14% | 9% | 16.8× | 8.6% | +3.5% |
| Hims & Hers Health HIMS | United States | $6.07B | -8% | +28% | 0% | 128.9× | 54.9% | +73.6% |
| Labcorp LH | United States | $29.8B | +45% | +6% | 11% | 19.0× | 13.9% | 0.0% |
| Koninklijke Philips PHIA.AS | Netherlands | $29.8B | +24% | -1% | 10% | 16.5× | 5.7% | +0.6% |
| RadNet RDNT | United States | $5.98B | +31% | +19% | 5% | 129.7× | 41.8% | +13.7% |
| Concentra Group Holdings Parent CON | United States | $5.38B | +75% | +14% | 17% | 24.5× | 3.9% | +7.9% |
| BillionToOne BLLN | United States | $5.38B | +54% | +90% | 11% | 144.4× | 26.8% | +90.1% |
| Lifestance Health LFST | United States | $5.26B | +79% | +20% | 5% | 62.6× | 37.8% | +30.4% |
| Option Care Health OPCH | United States | $4.74B | +54% | +4% | 6% | 15.6× | 1.5% | +13.2% |
| Medicover MCOV-B.ST | Sweden | $4.14B | +36% | +6% | 7% | 38.3× | 20.8% | +20.2% |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% | +11.8% |
| Acadia Healthcare ACHC | United States | $3.44B | +47% | +4% | 10% | 18.7× | n/a | n/a |